Cytovia, Cellectis add CAR-T targets to preexisting cell therapy pact; BridgeBio, Helsinn unveil first program in R&D tie-up
NK cell biotech Cytovia and gene editing firm Cellectis are expanding upon their previous team-up.
The two biotechs announced yesterday they have expanded their collaboration of gene-edited, iPSC-derived NK and CAR-NK cells to include new CAR targets and development in China by Cytovia’s joint venture entity, CytoLynx Therapeutics.
The amended deal, which was originally agreed to in February, now includes a $20 million equity stake in Cytovia stock by Cellectis, up from $15 million, alongside up to $805 million in milestones and royalty payments.
Cellectis is granting Cytovia a worldwide license to use Cellectis’s custom-built TALENs — a gene editing system that was developed before the advent of CRISPR — under certain patent rights. This includes in China, enabling Cytovia to modify NK cells and address multiple gene-targets for several already-discussed oncology indications.
“We are pleased to expand the collaboration with Cellectis to enable Cytovia to develop iNK products,” said Cytovia’s CEO Daniel Teper in a prepared statement. — Paul Schloesser
BridgeBio, Helsinn announce first program from multibillion-dollar R&D pact
BridgeBio and Helsinn will co-develop and co-commercialize a GPX4 inhibitor the partners hope could be a first-of-its-kind drug across multiple tumor types as part of an overarching R&D pact between the two companies, according to a release.
The partners say the drug could eventually be used to treat more than 500,000 US cancer patients, though any potential market there is a long way off. The program is the first designated under a non-exclusive R&D pact signed between the two companies back in March with $2.45 billion in milestones on the line.
The two companies will split R&D and commercial costs for the GPX4 inhibitor program, assuming it gets there. — Kyle Blankenship